"None  PHOENIX Oct.   PRNewswire  Creative Medical Technology Holdings OTCQB  CELZ announced today completion of the safety data analysis on  patients with pharmacologicallyresistant erectile dysfunction treated with the Companys patented CaverStem procedure.    The trial sponsored by Creative Medical Technology Holdings was conducted at the University of California Los Angeles Harbor HospitalLA Biomed under Institutional Review Board IRB approval. An independent medical safety monitor was also appointed to review the patient data for safety and feasibility of administering bone marrow derived stem cells into patients with erectile dysfunction. The goal of this procedure is to regenerate blood vessels and smooth muscle parts of the penis that are not functioning properly in this patient population.    Based on establishment of safety of the CaverStem procedure in a formal universitybased clinical trial and independent confirmation of efficacy in an European clinical trial we have launched commercialization for the CaverStem procedure said Timothy Warbington President and Chief Executive Officer of Creative Medical Technology Holdings. Amongst other top urologists we have recruited a worldrenowned urologist as a lead physician to rollout the procedure. We anticipate that the procedure will be available to patients that meet the eligibility criteria within the next  days.    According to the National Institutes of Health approximately  million men in the United States suffer from Erectile Dysfunction of which  million do not respond to pharmacological treatments such as Viagra Levitra and Cialis.    The CaverStem procedure involves obtaining a small amount of bone marrow from the patient purifying the stem cells using a closed system device that is FDA cleared and then administering these cells in the same procedure into the patients penis said Thomas Ichim Ph.D Chief Scientific Officer and CoFounder of the Company. Having published the first peerreviewed paper on this procedure back in  together with internationally renowned urologists and stem cell experts it is very exciting for me to watch this translate from bench to bedside.    About Creative Medical Technology Holdings    Creative Medical Technology Holdings Inc. is a clinical stage biotechnology company currently trading on the OTCQB under the ticker symbol CELZ. For further information about the company go to creativemedicaltechnology.com.     Yiou et al. Intracavernous Injections of Bone Marrow Mononucleated Cells for Postradical Prostatectomy Erectile Dysfunction Final Results of the INSTIN Clinical Trial.Eur Urol Focus.  Jun . pii S https     https     Ichim et al. Intracavernous administration of bone marrow mononuclear cells a new method of treating erectile dysfunction J Transl Med.  Jun . https    ForwardLooking Statements    OTC Markets has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This news release may contain forwardlooking statements including but not limited to comments regarding the timing and content of upcoming clinical trials marketing efforts funding etc. Forwardlooking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings Inc. with the Securities and Exchange Commission and available on the Commissions website at     Related Links    httpcreativemedicaltechnology.com    httpcaverstem.com    SOURCE Creative Medical Technology Holdings Inc.    Related Links    httpcreativemedicaltechnology.com"